September 27, 2019
Synairgen uplifted by beginning results of phase 2 trial of antiviral therapy for COPD patients
Synairgen is confident to get a positive outcome in Part 2 study of Phase 2 trial of its antiviral therapy for Chronic Obstructive Pulmonary Disorder (COPD) patients, in which inhaled IFN-beta is being assessed when patients do have a confirmed respiratory virus infection, after the first part showed positive results.
